Adam Koppel, EVP, Strategy and Bus. Dev at Biogen, holds 0.00 shares in Cerevel Therapeutics Holdings (Ticker: CERE), holds 4.03M shares in Solid Biosciences (Ticker: SLDB), holds 487.50K shares in BCLS Acquisition (Ticker: BLSA).
Adam Koppel latest transaction was an Uninformative Sell of ―.
What was Adam Koppel's most profitable transaction?
Adam Koppel’s most profitable transaction was an Informative Buy of CERE stock on October 29, 2020. The return on the trade was 306.50%.
What is Adam Koppel's role in Biogen?
Adam Koppel's role in Biogen is EVP, Strategy and Bus. Dev.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.